TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32930112

Group type: EXPERIMENTAL
Intervention: TTF-1 positive patients
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: TTF-1 negative patients
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: TTF-1 negative with EGFR mutation positive
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: TTF-1 negative with CK7 positive
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: TTF-1 negative patients who received curative radiotherapy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: TTF-1 expression
Number of subjects: 200
Study: 35849276

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate at a dose of 250 mg/kg (at 8 mg/kg/min) once daily for 3 days along with therapeutic hypothermia
Number of subjects: 134

Group type: COMPARATOR
Intervention: Therapeutic hypothermia alone
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate and therapeutic hypothermia
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Secondary outcomes including neonatal mortality, major neurodevelopmental disability at 1 y of age, neurological status at discharge, level of oxidative stress markers, and adverse effects
Number of subjects: 134
Study: 34670201

Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (cTBS) administered over one of three stimulation targets in randomized order.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single administrations of cTBS over each target.
Number of subjects: 24
Study: 35979351

Group type: EXPERIMENTAL
Intervention: Belimumab treatment
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional treatments (historical controls)
Number of subjects: 82
Study: 32650730

Group type: EXPERIMENTAL
Intervention: CT scan findings showing increased interstitial markings
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: CT scan findings showing ground glass opacities
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Radiologist's impression of PJP being possible
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Radiologist's impression of PJP being likely
Number of subjects: 360

Group type: COMPARATOR
Intervention: Chest x-ray findings
Number of subjects: 360
Study: 34995162

Group type: EXPERIMENTAL
Intervention: Telehealth interventions for HIV prevention and treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remote adaptations to behavioral interventions for HIV prevention
Number of subjects: 0
Study: 34050628

Group type: EXPERIMENTAL
Intervention: Active bait boxes containing fipronil wick
Number of subjects: 622

Group type: COMPARATOR
Intervention: Placebo bait boxes (empty)
Number of subjects: 622
Study: 32157631

Group type: EXPERIMENTAL
Intervention: Whole-Brain Radiotherapy (WBRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hippocampal-Avoidant Whole-Brain Radiotherapy (HA-WBRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stereotactic Radiosurgery (SRS) or Surgery Alone
Number of subjects: 0
Study: 33326179

Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg/50 µl)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Ranibizumab (0.5 mg/50 µl)
Number of subjects: 38
Study: 36322102

Group type: EXPERIMENTAL
Intervention: Resection plus permanent implantation of a novel radiation device utilizing the gamma‐emitting isotope Cs‐131 embedded within bioresorbable collagen tiles
Number of subjects: 28
Study: 33859173

Group type: EXPERIMENTAL
Intervention: INTACT (Intact protein-based formula)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: PHw (Partially hydrolyzed whey-based formula)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: HPPHw (High-protein partially hydrolyzed whey-based formula)
Number of subjects: 35

Group type: COMPARATOR
Intervention: HM (Human milk)
Number of subjects: 35
Study: 32663660

Group type: EXPERIMENTAL
Intervention: Prolonged anticoagulation (intravenous unfractionated heparin, subcutaneous enoxaparin, or intravenous bivalirudin) for at least 48 hours after pPCI
Number of subjects: 2856

Group type: COMPARATOR
Intervention: Matching placebo (no anticoagulation) for at least 48 hours after pPCI
Number of subjects: 2856

Group type: EXPERIMENTAL
Intervention: Prolonged anticoagulation
Number of subjects: 2856

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 2856
Study: 36501211

Group type: EXPERIMENTAL
Intervention: Protein and pomegranate extract (Test group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Protein and maltodextrin (Control group)
Number of subjects: 30
Study: 32182276

Group type: EXPERIMENTAL
Intervention: Open condition (advance information about pitch type)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Random condition (no advance information about pitch type)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Continuity condition (same pitch type thrown consecutively)
Number of subjects: 26
Study: 35551533

Group type: EXPERIMENTAL
Intervention: Vaginal hormone-free moisturising cream
Number of subjects: 172

Group type: COMPARATOR
Intervention: Vaginal estriol (0.1%) cream
Number of subjects: 172
Study: 32897015

Group type: EXPERIMENTAL
Intervention: Nefradoz (150 mg, 2 times a day for 28-30 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (general recommendations and standard diet therapy for 28-30 days)
Number of subjects: 60
Study: 34371810

Group type: EXPERIMENTAL
Intervention: Curcumin (HydroCurcTM; 500 mg) with low dose iron (18 mg)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Curcumin (HydroCurcTM; 500 mg) with high dose iron (65 mg)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Low dose iron (18 mg) with curcumin placebo
Number of subjects: 155

Group type: COMPARATOR
Intervention: High dose iron (65 mg) with curcumin placebo
Number of subjects: 155
Study: 32395901

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block reversed with sugammadex
Number of subjects: 350

Group type: COMPARATOR
Intervention: Moderate neuromuscular block reversed with neostigmine
Number of subjects: 350
Study: 35397622

Group type: EXPERIMENTAL
Intervention: 90 g/day low-carbohydrate diet (LCD)
Number of subjects: 85

Group type: COMPARATOR
Intervention: TDD (control group)
Number of subjects: 85
Study: 33832346

Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine (FP) therapy
Number of subjects: 102
Study: 33298565

Group type: EXPERIMENTAL
Intervention: rAAV2/2‐ND4 (GS010)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups (rAAV2/2‐ND4 and sham)
Number of subjects: 37
Study: 35816053

Group type: EXPERIMENTAL
Intervention: BNT162b2 as second dose
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV‐19 as second dose
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: CoronaVac as second dose
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: BNT162b2 booster after heterologous CoronaVac and ChAdOx1 nCoV‐19
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Heterologous two-dose schedules
Number of subjects: 210
Study: 33628086

Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pyridostigmine 0.15 mg/kg + glycopyrrolate 0.4 mg (control group)
Number of subjects: 60
Study: 35532871

Group type: EXPERIMENTAL
Intervention: Intravenous ferric derisomaltose
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intravenous iron
Number of subjects: 102
Study: 36419388

Group type: EXPERIMENTAL
Intervention: BV-4051
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 33508779

Group type: EXPERIMENTAL
Intervention: Dehydration trial (humid heat at 40 °C, 60% relative humidity with exercise)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Hyperhydration trial (ingestion of lightly salted water)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ultrasound measurements
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ultrasound estimates of body fat percentage
Number of subjects: 11
Study: 32197627

Group type: EXPERIMENTAL
Intervention: Tailored cognitive behavioural therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive listening intervention
Number of subjects: 0
Study: 34591977

Group type: EXPERIMENTAL
Intervention: Docetaxel plus carboplatin (DCb) for six cycles
Number of subjects: 93

Group type: COMPARATOR
Intervention: Epirubicin plus cyclophosphamide for four cycles followed by docetaxel for four cycles (EC-D)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Overall survival (OS) and event-free survival (EFS) rates
Number of subjects: 93
Study: 33705165

Group type: EXPERIMENTAL
Intervention: TRACK intervention (behavioral exercises within three individual sessions)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: TRACK intervention
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (wait-list)
Number of subjects: 176
Study: 33264516

Group type: EXPERIMENTAL
Intervention: Bimagrumab 3 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bimagrumab 30 mg/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bimagrumab (both doses)
Number of subjects: 24
Study: 33427489

Group type: EXPERIMENTAL
Intervention: MACI with ABG
Number of subjects: 21
Study: 35843845

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric and supportive care assessments from a multidisciplinary team targeting unmet needs.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care (routine oncological management with referral to geriatrics based on discretion of the primary oncologist).
Number of subjects: 200
Study: 32901293

Group type: EXPERIMENTAL
Intervention: High sensitivity cardiac troponin T (HS‐cTnT) levels measured with a highly sensitive assay
Number of subjects: 442
Study: 35570159

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 727

Group type: COMPARATOR
Intervention: Phacoemulsification cataract surgery (PCS)
Number of subjects: 727
Study: 32800842

Group type: EXPERIMENTAL
Intervention: Home BP treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Predialysis BP treatment
Number of subjects: 50
Study: 32544142

Group type: EXPERIMENTAL
Intervention: Color-only method
Number of subjects: 25

Group type: COMPARATOR
Intervention: FDA-approved validation method
Number of subjects: 25
Study: 32397994

Group type: EXPERIMENTAL
Intervention: Outreach hospital rehabilitation services in residential aged care
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Strategies in addition to investment in rehabilitation services
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Increased focus on rehabilitation in residential care
Number of subjects: 13
Study: 35191173

Group type: EXPERIMENTAL
Intervention: Nature-based physical activity (walk-in nature)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sit-in nature (control group)
Number of subjects: 0
Study: 34076379

Group type: EXPERIMENTAL
Intervention: Passiflora incarnata L
Number of subjects: 20

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 20
Study: 35726085

Group type: EXPERIMENTAL
Intervention: Digital therapeutics (DTx) + guideline-based lifestyle modification consultation treatment as usual (TAU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TAU-only strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incremental cost-effectiveness ratio (ICER) for DTx + TAU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probability of DTx being cost-effective
Number of subjects: 0
Study: 33231256

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy for insomnia (CBTi)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 91
Study: 33105371

Group type: EXPERIMENTAL
Intervention: Low artifact removal during controlled breathing
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Low artifact removal during spontaneous breathing
Number of subjects: 41

Group type: COMPARATOR
Intervention: Strong artifact removal
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Time-domain and nonlinear parameters
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: HRV monitoring
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Intersession differences in HRV measurements <30%
Number of subjects: 41
Study: 35545190

Group type: EXPERIMENTAL
Intervention: Computer-guided sodium hyaluronate injections
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional sodium hyaluronate injections
Number of subjects: 40
Study: 33576545

Group type: EXPERIMENTAL
Intervention: Oxycodone 10 mg/Acetaminophen 650 mg
Number of subjects: 154

Group type: COMPARATOR
Intervention: Acetaminophen 650 mg
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Oxycodone/Acetaminophen
Number of subjects: 154

Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 154
Study: 33196737

Group type: EXPERIMENTAL
Intervention: USCCM cream and serum pre‐ and post‐ ablative resurfacing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle pre‐procedure cream
Number of subjects: 20
Study: 35763871

Group type: EXPERIMENTAL
Intervention: 9 cycles of ifosfamide, vincristine and dactinomycin; some patients also received doxorubicin and/or maintenance if enrolled in the randomised studies.
Number of subjects: 143
Study: 34665204

Group type: EXPERIMENTAL
Intervention: Varenicline plus nicotine patch for 12 weeks
Number of subjects: 1251

Group type: COMPARATOR
Intervention: Varenicline monotherapy for 12 weeks
Number of subjects: 1251

Group type: EXPERIMENTAL
Intervention: Varenicline plus nicotine patch for 24 weeks
Number of subjects: 1251

Group type: COMPARATOR
Intervention: Varenicline monotherapy for 24 weeks
Number of subjects: 1251

Group type: EXPERIMENTAL
Intervention: Nausea occurrence across groups
Number of subjects: 1251

Group type: EXPERIMENTAL
Intervention: Insomnia occurrence across groups
Number of subjects: 1251
Study: 32304283

Group type: EXPERIMENTAL
Intervention: Metformin/sitagliptin dual therapy for 16 weeks
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Metformin/sitagliptin triple therapy for 24 weeks
Number of subjects: 972

Group type: COMPARATOR
Intervention: Dual therapy
Number of subjects: 972

Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 972
Study: 36074950

Group type: EXPERIMENTAL
Intervention: In situ lithotripsy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Relocation lithotripsy
Number of subjects: 68
Study: 32720187

Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin (TI)
Number of subjects: 5505

Group type: COMPARATOR
Intervention: Technosphere inhalation powder without insulin (TP; placebo)
Number of subjects: 5505

Group type: COMPARATOR
Intervention: Active-comparator treatment
Number of subjects: 5505

Group type: EXPERIMENTAL
Intervention: Active TI therapy
Number of subjects: 5505

Group type: EXPERIMENTAL
Intervention: Radiographic monitoring
Number of subjects: 5505
Study: 33121885

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 557

Group type: COMPARATOR
Intervention: Neuraxial anesthesia
Number of subjects: 557
Study: 34107851

Group type: EXPERIMENTAL
Intervention: Musculoskeletal ultrasound programme (MUSP) at baseline
Number of subjects: 126

Group type: COMPARATOR
Intervention: No MUSP (control group)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Musculoskeletal ultrasound programme (MUSP)
Number of subjects: 126
Study: 32567340

Group type: EXPERIMENTAL
Intervention: Three-session disclosure-support intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 80
Study: 32394650

Group type: EXPERIMENTAL
Intervention: Moxibustion intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional intervention
Number of subjects: 100
Study: 35653732

Group type: EXPERIMENTAL
Intervention: Dual-hormone algorithm-assisted insulin delivery (DH-AID)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Single-hormone algorithm-assisted insulin delivery (SH-AID)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 58
Study: 34782232

Group type: EXPERIMENTAL
Intervention: PROficiency based StePwise Endovascular Curricular Training (PROSPECT)
Number of subjects: 48
Study: 33638931

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study: 35722816

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 219

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 219
Study: 32734751

Group type: COMPARATOR
Intervention: Virtual Training (VT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Plyometric Training (PT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 55
Study: 35445362

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure in Primary Care (PE-PC)
Number of subjects: 30
Study: 36086254

Group type: EXPERIMENTAL
Intervention: Computerized Biofeedback-based Balance Intervention (CBBI)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (TBI-CTL)
Number of subjects: 13
Study: 33524314

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (300 mg orally once daily for 3 years)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (oral once daily for 3 years)
Number of subjects: 160
Study: 36056410

Group type: EXPERIMENTAL
Intervention: Resilient liners (RL)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Non-resilient liners (NRL)
Number of subjects: 132
Study: 33316362

Group type: EXPERIMENTAL
Intervention: Adaptive planning (AP) using a minimization algorithm, 36 Gy in 6 weekly fractions.
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard planning (SP), 36 Gy in 6 weekly fractions.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 65
Study: 616562814

Group type: EXPERIMENTAL
Intervention: Healthy Life Practice (HLP) education, 10 health education sessions
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 101
Study: 34031151

Group type: EXPERIMENTAL
Intervention: Enhanced support (additional clinical backfill funding and unit-level QI microcoaching)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard support (QI toolkit and regional-level support for a midwife/obstetric 'champion')
Number of subjects: 48
Study: 35578194

Group type: EXPERIMENTAL
Intervention: Stabilizing group treatment (20 sessions, add-on to individual therapy)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Individual therapy alone
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Stabilizing group treatment
Number of subjects: 59
Study: 34333783

Group type: EXPERIMENTAL
Intervention: Communication via social media before the operation (group 2)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Communication via social media before and after the operation (group 3)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Communication via social media only after the operation (group 1)
Number of subjects: 143

Group type: COMPARATOR
Intervention: No communication on social media (control group 4)
Number of subjects: 143
Study: 32448387

Group type: EXPERIMENTAL
Intervention: ePain (6-week online pain management programme)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34275193

Group type: EXPERIMENTAL
Intervention: Air polishing followed by ultrasonic calculus removal (A+US)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Traditional full-mouth ultrasonic debridement followed by polishing with a rubber cup and prophylactic paste (US+P)
Number of subjects: 41
Study: 35758504

Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin A (50 units)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Chinese botulinum toxin type A (CBA) (50 units)
Number of subjects: 102
Study: 33641535

Group type: EXPERIMENTAL
Intervention: Active Ankle Exercise with Intermittent Pneumatic Compression (IPC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Active Ankle Exercise (AAE) alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intermittent Pneumatic Compression (IPC) alone
Number of subjects: 20
Study: 32932393

Group type: EXPERIMENTAL
Intervention: Scleral lenses with oxygen permeability of 65 Dk
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Scleral lenses with oxygen permeability of ≥100 Dk
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: All oxygen‐permeable lenses
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ≤125 Dk lenses
Number of subjects: 15

Group type: COMPARATOR
Intervention: Soft lenses
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 180+ Dk lenses
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Scleral lens wear
Number of subjects: 15
Study: 34860287

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 33637544

Group type: EXPERIMENTAL
Intervention: Peer-Assisted Lifestyle (PAL) intervention
Number of subjects: 461

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 461
Study: 33085967

Group type: EXPERIMENTAL
Intervention: Ticagrelor plus placebo
Number of subjects: 7119
Study: 35301728

Group type: EXPERIMENTAL
Intervention: Problem-oriented training strategy
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Strengths-oriented training strategy
Number of subjects: 96
Study: 33710658

Group type: EXPERIMENTAL
Intervention: Low-pressure testing
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: High-pressure testing with pedicle fat
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Harvesting the vein with the pedicle fat
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional saphenous vein graft preparation with low-pressure distension
Number of subjects: 96
Study: 35666503

Group type: EXPERIMENTAL
Intervention: Children's Healthy Living intervention
Number of subjects: 9840
Study: 32655132

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 35745256

Group type: EXPERIMENTAL
Intervention: Moderate‐to‐high intensity aerobic and strengthening training
Number of subjects: 178

Group type: COMPARATOR
Intervention: Low‐impact PA
Number of subjects: 178
Study: 33910498

Group type: EXPERIMENTAL
Intervention: Autism spectrum disorder
Number of subjects: 14654

Group type: COMPARATOR
Intervention: Population controls
Number of subjects: 14654
Study: 32561500

Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 42